Current Report Filing (8-k)
December 18 2020 - 11:20AM
Edgar (US Regulatory)
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
Washington, DC 20549
|
|
FORM 8-K
|
CURRENT REPORT Pursuant
|
to Section 13 or 15(d) of the
|
Securities Exchange Act of 1934
|
|
Date of report (Date of earliest event reported): December 17, 2020
|
Bionik
Laboratories Corp.
(Exact Name
of Registrant as Specified in Its Charter)
Delaware
|
|
000-54717
|
|
27-1340346
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: (416) 640-7887
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol
|
Name
of each exchange on which registered
|
Not applicable
|
Not applicable
|
Not applicable
|
|
Item
1.01
|
Entry
Into A Material Agreement.
|
The information set forth in Item 2.03
is incorporated by reference into this Item 1.01.
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant
|
On December 17, 2020, Bionik
Laboratories Corp. amended the terms of its existing promissory note in the principal amount of $2,000,000 (the
“Note”) with Celeste Management, pursuant to an Allonge (the “Allonge”), to extend the first interest
payment date to March 31, 2021 (the “First Interest Payment Date”), with quarterly interest payments accruing for
the periods ending on the three month, six month and nine month anniversaries of the issue date of the Note nevertheless
being payable, without further interest thereon, pro rata from the First Interest Payment Date through the maturity date of
the Note.
The foregoing is a brief description of
the Allonge and is qualified in its entirety by reference to the full text of the Allonge, which is included as Exhibit 10.1 to
this Current Report on Form 8-K and which is incorporated herein by reference.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: December 18, 2020
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
By:
|
/s/ Richard Russo Jr.
|
|
Name:
|
Richard Russo Jr.
|
|
Title:
|
Chief Financial Officer
|
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jul 2023 to Jul 2024